# Denali Therapeutics (DNLI): value investors who own it

0 value investors held Denali Therapeutics in their Q3 2026 13F. See who bought, sold and how ownership has changed by quarter.

## 13F holders

| Manager | Portfolio | Value | Change | Quarters held |
| --- | --- | --- | --- | --- |
| Polen Capital Management | 0.0% | $0k | Sold out | 2 |

## Directors buying and selling (Form 4, last 12 months)

| Date | Who | Role | Bought or sold | Shares | Value |
| --- | --- | --- | --- | --- | --- |
| 2026-09-04 | Chin Peter Scott | Chief Medical Officer | Sold | 1654 | $37k |
| 2026-09-02 | Thornberry Nancy | Director | Sold | 10824 | $247k |
| 2026-09-02 | Thornberry Nancy | Director | Sold | 615 | $15k |
| 2026-09-01 | Schuth Alexander O. | COFO and Secretary | Sold | 2768 | $65k |
| 2026-08-11 | Schuth Alexander O. | COFO and Secretary | Sold | 2857 | $72k |

Source: SEC filings, via moatshark (https://www.moatshark.com/s/dnli). Values traded and returns are estimates. Not investment advice. Built 2026-10-21.